• Mubritinib-HSA Interaction: Insights into Pharmacokinetics a

  2026-07-09

  This study elucidates how Mubritinib (TAK 165), a mitochondrial complex I inhibitor initially developed as a HER2 kinase inhibitor, interacts with human serum albumin (HSA) at the molecular level. Understanding this interaction clarifies Mubritinib's pharmacokinetic behavior, informing its use in cancer and metabolic disease research.

• BRD4 Inhibition Enhances Erastin-Induced Ferroptosis via ROS

  2026-07-08

  The referenced study demonstrates that BRD4 inhibition, including with I-BET-762, markedly potentiates erastin-induced ferroptosis across several cell lines by promoting ROS accumulation and suppressing FSP1 expression. These findings clarify mechanistic underpinnings for combining BET inhibitors with ferroptosis inducers in cancer biology research.

• Indomethacin Sodium Trihydrate: Reliable Solutions for Cell

  2026-07-08

  This scenario-driven guide demonstrates how Indomethacin Sodium Trihydrate (SKU C6491) addresses core challenges in cell viability, proliferation, and cytotoxicity assays. Drawing on practical questions, published evidence, and product-specific advantages, it equips life science researchers with data-backed, workflow-optimized strategies for inflammation and pathway studies.

• Axitinib (AG 013736): Optimizing Angiogenesis Inhibition Ass

  2026-07-07

  Axitinib (AG 013736) empowers researchers with unmatched selectivity for VEGFR1/2/3, enabling precise modulation of angiogenesis and tumor growth in both in vitro and in vivo models. This article delivers data-driven protocols, troubleshooting insights, and advanced workflows to maximize reproducibility and translational relevance in cancer biology research.

• 5-Methyl-CTP in mRNA Vaccines: Engineering Stability for Tra

  2026-07-07

  Explore how 5-Methyl-CTP enhances mRNA stability and translation efficiency in advanced mRNA vaccine and therapeutic development. This article offers a unique, evidence-driven perspective on integrating 5-methyl modified cytidine triphosphate in modern in vitro transcription workflows.

• LY2228820: Dual-Action p38 MAPK Inhibition and Phosphatase M

  2026-07-06

  Explore the unique dual-action mechanism of LY2228820, a potent p38 MAP kinase inhibitor, and discover how its conformational effects on kinase dephosphorylation open new frontiers for anti-inflammatory and cancer research workflows.

• Applied Workflows with Angiotensin 1/2 (2-7) Peptide in RAS

  2026-07-06

  Angiotensin 1/2 (2-7) peptide delivers unmatched sequence specificity and solubility for modeling renin-angiotensin signaling in blood pressure and viral pathogenesis studies. Discover optimized protocols, troubleshooting strategies, and the latest cross-domain insights that set this APExBIO product apart.

• MEG3 Regulates NiO Nanoparticle-Induced Pulmonary Fibrosis v

  2026-07-05

  This study elucidates how long noncoding RNA MEG3 modulates nickel oxide nanoparticle-induced pulmonary fibrosis by regulating TGF-β1-mediated PI3K/AKT signaling. The findings offer mechanistic clarity for researchers targeting fibrotic pathways and demonstrate the translational potential of PI3K inhibition strategies in nanoparticle toxicity models.

• GW4064: Non-Steroidal FXR Agonist for Advanced Metabolic Res

  2026-07-04

  GW4064 is a potent, non-steroidal FXR agonist that enables precise modulation of bile acid, cholesterol, and triglyceride pathways in preclinical studies. This article details optimized experimental workflows, comparative advantages, and troubleshooting tactics for leveraging GW4064 in metabolic and liver injury models, with actionable insights anchored in the latest research.

• AI-Powered Discovery of Senolytics: Methods and Implications

  2026-07-03

  The referenced study demonstrates the use of machine learning to identify novel senolytic compounds by leveraging published data, significantly reducing screening costs and expanding the senolytic chemical space. Its findings have practical implications for aging, cancer, and disease research by enabling more targeted elimination of senescent cells.

• N-MYC/eIF4G1 Axis in inv(16) Acute Myeloid Leukemia Survival

  2026-07-03

  The study by Peramangalam et al. uncovers a critical regulatory axis in inv(16) acute myeloid leukemia, demonstrating that N-MYC drives leukemic cell survival through eIF4G1. By elucidating these mechanisms and the impact of targeted CBFβ-SMMHC inhibition, the research offers new translational directions for acute myeloid leukemia investigation.

• SAR131675: VEGFR-3 Inhibitor Workflows for Lymphangiogenesis

  2026-07-02

  SAR131675 empowers researchers to dissect VEGFR-3-driven lymphangiogenesis with unmatched selectivity and potency. This guide translates bench evidence into actionable workflows, troubleshooting advice, and advanced applications that set SAR131675 apart for preclinical fibrosis and tumor models.

• Methyl-β-cyclodextrin: Technical Parameters for Membrane Stu

  2026-07-02

  Methyl-β-cyclodextrin enables controlled extraction of cholesterol and select lipids from cellular membranes, supporting studies of membrane fluidity, lipid raft disruption, and cholesterol-dependent signaling. It is unsuitable for diagnostic or medical applications and should be applied strictly within research workflows using recommended protocols.

• Taltirelin Protects Dopaminergic Neurons in PD Models

  2026-07-01

  This study demonstrates that Taltirelin, a long-acting TRH analog, robustly protects dopaminergic neurons against neurotoxicity in both MPTP and rotenone-induced Parkinson’s disease models. The findings clarify mechanisms involving inhibition of MAO-B, reduction of oxidative stress, and blockade of pathological protein cleavage, supporting Taltirelin as a promising neuroprotective agent in translational research.

• SAR131675: A Potent, Selective VEGFR-3 Inhibitor for Researc

  2026-07-01

  SAR131675 is a highly selective ATP-competitive VEGFR-3 inhibitor with nanomolar potency and minimal off-target activity. Its validated anti-lymphangiogenic and anti-angiogenic efficacy underpins its use in tumor and fibrosis models. The compound’s discontinued development highlights important safety considerations for translational research.

408 records 9/28 page Previous Next First page 上5页 678910 下5页 Last page